Identification of novel compound heterozygous mutations in ACO2 in a patient with progressive cerebral and cerebellar atrophy.
Masahide FukadaKeitaro YamadaShima EdaKen InoueChihiro OhbaNaomichi MatsumotoHirotomo SaitsuAtsuo NakayamaPublished in: Molecular genetics & genomic medicine (2019)
The marked reduction of aconitase activity in patient fibroblasts was due to the combination of decreased aconitase 2 amount and activity due to mutations. Reduced aconitase activity directly suppresses the TCA cycle, resulting in mitochondrial dysfunction, which may lead to symptoms similar to those observed in mitochondrial diseases.